Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Robillard

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Blood|December 15, 1996
Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasoneD Puthier, R Bataille, S Barillé, et al.
Blood|October 15, 1994
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cellsC Pellat-Deceunynck, R Bataille, N Robillard, et al.
Hematology and Cell Therapy|March 14, 1998
Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis productsS Hermouet, A E Niaussat, A Briec, et al.
British Journal of Haematology|February 1, 1996
G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myelomaB Mahé, N Milpied, S Hermouet, et al.
British Journal of Haematology|June 10, 2000
IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12R Garand, S S Sahota, H Avet-Loiseau, et al.
British Journal of Haematology|August 1, 1995
Minimally differentiated erythroleukaemia (AML M6 'variant'): a rare subset of AML distinct from AML M6. Groupe Français d'Hématologie CellulaireR Garand, E Duchayne, D Blanchard, et al.
Leukemia|May 20, 2005
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survivalS Wuillème-Toumi, N Robillard, P Gomez, et al.
Leukemia|February 20, 1999
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancyD Puthier, C Pellat-Deceunynck, S Barillé, et al.
Leukemia|October 31, 2008
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 casesP Chevallier, N Robillard, G Houille, et al.
Leukemia|December 9, 1998
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myelomaC Pellat-Deceunynck, S Barillé, G Jego, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Blood|December 15, 1996
Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasoneD Puthier, R Bataille, S Barillé, et al.
Blood|October 15, 1994
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cellsC Pellat-Deceunynck, R Bataille, N Robillard, et al.
Hematology and Cell Therapy|March 14, 1998
Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis productsS Hermouet, A E Niaussat, A Briec, et al.
British Journal of Haematology|February 1, 1996
G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myelomaB Mahé, N Milpied, S Hermouet, et al.
British Journal of Haematology|June 10, 2000
IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12R Garand, S S Sahota, H Avet-Loiseau, et al.
British Journal of Haematology|August 1, 1995
Minimally differentiated erythroleukaemia (AML M6 'variant'): a rare subset of AML distinct from AML M6. Groupe Français d'Hématologie CellulaireR Garand, E Duchayne, D Blanchard, et al.
Leukemia|May 20, 2005
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survivalS Wuillème-Toumi, N Robillard, P Gomez, et al.
Leukemia|February 20, 1999
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancyD Puthier, C Pellat-Deceunynck, S Barillé, et al.
Leukemia|October 31, 2008
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 casesP Chevallier, N Robillard, G Houille, et al.
Leukemia|December 9, 1998
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myelomaC Pellat-Deceunynck, S Barillé, G Jego, et al.
Pageof 8